FORM	4
------	---

(D.,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Find of Type Responses)											
1. Name and Address of Reporting Person [*] Rodgers Richard J		2. Issuer Name and Dcuphire Pharma					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) C/O OCUPHIRE PHARMA, INC., 3 GRAND RIVER AVE, SUITE 120	= 0 0 0	3. Date of Earliest Transaction (Month/Day/Year) 11/19/2020						Officer (give title below)Ot	ner (specify belo	w)	
(Street) FARMINGTON HILLS, MI 48335	4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
Title of Security 2. Transaction Date (Month/Day/Ye		-	Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	Ownership of Indire Form: Benefici	Beneficial	
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common Stock	11/19/2020		Р		17,730	A	<u>(1)</u>	23,640	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
Security (Instr. 3)	Conversion	Date (Month/Day/Year)	Execution Date, if	Code	tion)	5. Number of Deriva Securities Acquired or Dispos of (D) (Instr. 3, and 5)	tive s (A) sed	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s)	Derivative Security: Direct (D) or Indirect (I)	Beneficial
				Code	v	(A)	(D)	Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Series A Warrant (right to buy)	\$ 4.4795 (2)	11/19/2020		Р		26,789		11/19/2020	11/19/2025	Common Stock	26,789	<u>(1)</u>	26,789	D	
Series B Warrant (right to buy)	\$ 0.0001	11/19/2020		Р		3,148 (2)		11/19/2020	01/28/2022	Common Stock	3,148	<u>(1)</u>	3,148	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Rodgers Richard J C/O OCUPHIRE PHARMA, INC. 37000 GRAND RIVER AVE, SUITE 120 FARMINGTON HILLS, MI 48335	Х						

Signatures

/s/ Emily J. Johns, by Power of Attorney	11/25/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of \$100,000.
- (2) Subject to adjustment based on certain price reset provisions.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} If the form is filed by more than one reporting person, see Instruction 4(b)(v).